Inhalers - Medical Devices Pipeline Assessment, 2018
Region:Global
Product Code:GDME0611EPD
June 2018
311
About the Report
Inhalers-Medical Devices Pipeline Assessment, 2018
Summary
GlobalData's Medical Devices sector report, Inhalers-Medical Devices Pipeline Assessment, 2018 provides an overview of Inhalers currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Inhalers pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Inhalers under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Inhalers and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to buy
The report enables you to-
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Inhalers under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
Scope of the Report
Products
Companies
Acorda Therapeutics Inc
Adamis Pharmaceuticals Corp
Advent Pharmaceuticals Pty Ltd
Aespira Ltd.
AKELA Pharma Inc.
Alexza Pharmaceuticals Inc
Aradigm Corp
AstraZeneca Plc
Bayer AG
Bellerophon Therapeutics Inc
Bespak Europe Ltd
Boehringer Ingelheim GmbH
Circassia Pharmaceuticals Plc
Drexel University
FocusStart LLC
GlaxoSmithKline Plc
MannKind Corp
Medihale Ltd
Monash University
Nanotherapeutics Inc
Nektar Therapeutics
Nicoventures Trading Ltd
North Carolina State University
Novartis AG
OPKO Health Inc
Perrigo Company Plc
Pharmaxis Ltd
Pneuma Respiratory Inc
Resolve Digital Health Inc
Respira Therapeutics Inc
Sandoz International GmbH
Sheffield Hallam University
Sun Pharma Advanced Research Company Ltd
Tetra Bio-Pharma Inc
Teva Pharmaceutical Industries Ltd
United Therapeutics Corp
University of Kansas
University of Texas Medical Branch at Galveston
Uscom Ltd.
Vectura Group Plc
Verona Pharma Plc
Virginia Commonwealth University
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 11
2 Introduction 12
2.1 Inhalers Overview 12
3 Products under Development 13
3.1 Inhalers-Pipeline Products by Stage of Development 13
3.2 Inhalers-Pipeline Products by Segment 14
3.3 Inhalers-Pipeline Products by Territory 15
3.4 Inhalers-Pipeline Products by Regulatory Path 17
3.5 Inhalers-Pipeline Products by Estimated Approval Date 18
3.6 Inhalers-Ongoing Clinical Trials 19
4 Inhalers-Pipeline Products under Development by Companies 20
4.1 Inhalers Companies-Pipeline Products by Stage of Development 20
4.2 Inhalers-Pipeline Products by Stage of Development 22
5 Inhalers Companies and Product Overview 24
5.1 Acorda Therapeutics Inc Company Overview 24
5.2 Adamis Pharmaceuticals Corp Company Overview 27
5.3 Advent Pharmaceuticals Pty Ltd Company Overview 28
5.4 Aespira Ltd. Company Overview 29
5.5 AKELA Pharma Inc. (Inactive) Company Overview 30
5.6 Alexza Pharmaceuticals Inc Company Overview 31
5.7 Aradigm Corp Company Overview 33
5.8 AstraZeneca Plc Company Overview 34
5.9 Bayer AG Company Overview 35
5.10 Bellerophon Therapeutics Inc Company Overview 36
5.11 Bespak Europe Ltd Company Overview 37
5.12 Boehringer Ingelheim GmbH Company Overview 38
5.13 Circassia Pharmaceuticals Plc Company Overview 39
5.14 Drexel University Company Overview 40
5.15 FocusStart LLC Company Overview 41
5.16 GlaxoSmithKline Plc Company Overview 42
5.17 MannKind Corp Company Overview 43
5.18 Medihale Ltd (Inactive) Company Overview 45
5.19 Monash University Company Overview 46
5.20 Nanotherapeutics Inc (Inactive) Company Overview 47
5.21 Nektar Therapeutics Company Overview 49
5.22 Nicoventures Trading Ltd Company Overview 50
5.23 North Carolina State University Company Overview 51
5.24 Novartis AG Company Overview 52
5.25 OPKO Health Inc Company Overview 53
5.26 Perrigo Company Plc Company Overview 54
5.27 Pharmaxis Ltd Company Overview 55
5.28 Pneuma Respiratory Inc Company Overview 56
5.29 Resolve Digital Health Inc Company Overview 57
5.30 Respira Therapeutics Inc Company Overview 58
5.31 Sandoz International GmbH Company Overview 59
5.32 Sheffield Hallam University Company Overview 61
5.33 Sun Pharma Advanced Research Company Ltd Company Overview 62
5.34 Tetra Bio-Pharma Inc Company Overview 63
5.35 Teva Pharmaceutical Industries Ltd Company Overview 66
5.36 United Therapeutics Corp Company Overview 68
5.37 University of Kansas Company Overview 71
5.38 University of Texas Medical Branch at Galveston Company Overview 72
5.39 Uscom Ltd. Company Overview 73
5.40 Vectura Group Plc Company Overview 74
5.41 Verona Pharma Plc Company Overview 77
5.42 Virginia Commonwealth University Company Overview 78
6 Inhalers- Recent Developments 79
6.1 Jun 07, 2018: MannKind Successfully Completes Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension Advancing Development to Next Phase 79
6.2 Jun 01, 2018: Vectura Group Appoints Anne Whitaker As Non-Executive Director 79
6.3 May 24, 2018: Adherium Announces Appointment of David Allinson as Chief Financial Officer 80
6.4 May 21, 2018: 3M forms sustainability and product stewardship organization 80
6.5 May 17, 2018: New England Journal of Medicine publishes two trials for Symbicort as an anti-inflammatory reliever therapy as needed in mild asthma 80
6.6 May 16, 2018: Novartis announces changes to the Executive Committee 82
6.7 May 16, 2018: At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth 84
6.8 May 14, 2018: Medical Developments International: Trading Update 85
6.9 May 10, 2018: Adamis Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update 85
6.10 May 10, 2018: Nektar Therapeutics Reports Financial Results for the First Quarter of 2018 86
6.11 May 10, 2018: Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results 90
6.12 May 10, 2018: Novartis India reconstitutes Board appoints Milan Paleja as Vice Chairman Managing Director 91
6.13 May 09, 2018: 3M Announces New Leadership Appointment 91
6.14 May 09, 2018: MannKind Reports 2018 First Quarter Financial Results 92
6.15 May 09, 2018: Simon Dingemans, Chief Financial Officer, to retire from GSK 93
6.16 May 09, 2018: Savara Reports First Quarter 2018 Financial Results and Provides Business Update 93
6.17 May 08, 2018: OPKO Health Announces First Quarter 2018 Financial Results 95
6.18 May 03, 2018: Teva Reports First Quarter 2018 Financial Results 96
6.19 May 02, 2018: Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 6% in local currencies in the first three months of 2018 102
6.20 May 01, 2018: OPKO Health Appoints Geoff Monk General Manager at BioReference Laboratories 103
6.21 Apr 30, 2018: Adherium: Appendix 4C-Quarterly cash flow report to March 31 2018 103
6.22 Apr 26, 2018: Consort Medical: Director Declaration 103
6.23 Apr 25, 2018: Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home 104
6.24 Apr 25, 2018: Boehringer Ingelheim has a very successful 2017 financial year 104
6.25 Apr 24, 2018: Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD 105
6.26 Apr 20, 2018: Vectura Announces Senior Management Change 107
6.27 Apr 20, 2018: Vectura Group: Directorate Change-Chief Financial Officer 107
6.28 Apr 19, 2018: Boehringer Ingelheim and HealthPrize Expand Successful Digital Patient Support Program 108
6.29 Apr 19, 2018: Novartis delivered a strong first quarter and acted to become a more focused medicines company 109
6.30 Apr 19, 2018: Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer 113
6.31 Apr 18, 2018: Landmark IMPACT study published in NEJM shows significant benefits of Trelegy Ellipta for patients with COPD 114
6.32 Apr 18, 2018: GlaxoSmithKline Names Kevin Sin as new Senior Vice President and Head of Worldwide Business Development for Research & Development 115
6.33 Apr 16, 2018: Pneuma Respiratory Appoints Rich Gimigliano As Chief Financial Officer 116
6.34 Apr 16, 2018: Cipla: US FDA conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility 116
6.35 Apr 09, 2018: Pneuma Respiratory Appoints Dr. Steven Kesten as President and Chief Medical Officer 117
6.36 Apr 04, 2018: Tetra Bio-Pharma Initiates Enrolment of Patients in Phase 3 PPP001 Smokable Cannabis Pellet Study 117
7 Appendix 307
7.1 Methodology 307
7.2 About GlobalData 310
7.3 Contact Us 310
7.4 Disclaimer 310
Research Methodology
Why Buy From Us?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.